Santen Inc.

4 marketed · 2 in Phase 3

Quick facts

DE-117 · Ophthalmology
DE-117 is a selective rho kinase (ROCK) inhibitor that reduces intraocular pressure by improving aqueous humor outflow through the trabecular meshwork and Schlemm's canal.
DE-117 Ophthalmic Solution · Ophthalmology
DE-117 is a selective rho kinase (ROCK) inhibitor that reduces intraocular pressure by increasing uveoscleral outflow of aqueous humor.

DE-101 ophthalmic suspension · Ophthalmology
DE-101 ophthalmic suspension is an anti-inflammatory agent that reduces inflammation in the eye.
DE-110 ophthalmic suspension high dose
DE-110 ophthalmic suspension low dose
DE-117 Middle Dose ophthalmic solution · Ophthalmology
DE-117 is a selective rho kinase (ROCK) inhibitor that reduces intraocular pressure by improving aqueous humor outflow through the trabecular meshwork and Schlemm's canal.
DE-117 Ophthalmic Solution BID · Ophthalmology
DE-117 Ophthalmic Solution BID is an anti-inflammatory agent.
DE-117 Ophthalmic Solution QD
DE-117 is a selective EP2 receptor agonist that lowers intraocular pressure through increased uveoscleral outflow.
DE-120
DE-126 Ophthalmic Solution 0.002% QD
STN1010904 ophthalmic suspension 0.1% BID

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

Top marketed products include 0.0015% tafluprost, 0.005% Latanoprost Ophthalmic Solution, 1.5% levofloxacin ophthalmic solution, Lucentis.

Santen Inc. has 2 drugs in Phase 3, 9 in Phase 2, 4 in Phase 1. Late-stage candidates include DE-117, DE-117 Ophthalmic Solution.